OR WAIT null SECS
Click here to read the articles and download the PDF
A conversation with Matthew Bardell, managing director, nVentic, about a perhaps overlooked but useful strategic component of company performance and overall business benchmarks: inventory optimization.
Making sense of the accelerating trends and challenges—including store closings, pharmacy deserts, and the rise of polypharmacy.
Even as pharma technology evolves, and payers argue over reimbursement practices throughout healthcare, drug wholesaling is a thriving business.
November 09, 2023
SVP and Managing Director for Blue Fin Group offers a synopsis of the conference opener.
Session explains how to use this information to help bolster market intelligence, market access, and affordability strategies.
Conference presentation explores groundbreaking topics impacting the pharma industry.
Director of Berkeley Research Group explains changes to 340B moving forward.
Berkeley Research Group executive speaks about the role of manufacturers in 340B pricing.
Berkeley Research Group Director discusses what to expect at his upcoming session.
Fruquintinib (Fruzaqla) is a significant new therapy for patients who have had limited options to treat metastatic colorectal cancer.
November 08, 2023
Tirzepatide (Zepbound; Eli Lilly and Company) will hit the US market by the end of 2023 with a list price of $1,059.87.
Session explores how on-market products have done, and what to expect from new biosimilars.
Rexulti was found to be a well-tolerated treatment for the debilitating symptoms of agitation associated with dementia due to Alzheimer’s disease.